Jeremy Hobart

Measuring the impact of MS on walking ability

Jeremy Hobart, Afsane Riazi, Donna L. Lamping et al. · Neurology · 2003 · 806 citations

Health Professions, Rehabilitation Medicine, Functional Movement Assessment +16

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force

Marc K. Walton, John H. Powers, Jeremy Hobart et al. · Value in Health · 2015 · 318 citations · Full text

Pharmacy, Clinical Sciences, Outcomes Research +13

MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial

John Zajicek, Jeremy Hobart, Anita Slade et al. · Journal of Neurology Neurosurgery & Psychiatry · 2012 · 275 citations · Full text

Medicine, Neurology, Pharmacotherapy +16

Evidence-based measurement

Jeremy Hobart, Donna L. Lamping, Jenny Freeman et al. · Neurology · 2001 · 237 citations

Education, Rehabilitation Medicine, Functional Assessment +16